Características del manejo con dutasteride del paciente con hiperplasia prostática benigna y sonda uretrovesical en el Hospital Vicente Corral Moscoso. Cuenca. septiembre 2012- agosto 2013

Abstract

Benign prostatic hyperplasia it’s a very prevalent pathology in our environment, with a significant number of attentions, concluding in many of them surgical resolution as the treatment of choice. There are currently studies on the impact of drug therapy to reduce the symptomatology and stop the disease progression. In the present research we, the authors intend to demonstrate the capacity of dutasteride, a 5-alpha reductase inhibitor, in reducing the need of carrying an indwelling catheter in patients with diagnosed with benign obstructive prostatic hyperplasia.

Methods In order to obtain the data, an investigation was carried out of the patients who had received dutasteride in a 6 month lapse, using a formulary elaborated by the authors including the variables involved in the research.

Results We could observe that from de overall 121 patients with benign prostatic hyperplasia, 44 no longer needed de indwelling catheter at the end of the 6 months treatment; similarly it became clear that the PSA levels went from 45% in the range of 0-5ng/ml to 95% in a 6 month period of time under the treatment with dutasteride. Concerning the prostatic weight, reviewed through transrectal ultrasound scan, it was found a decrease in an average of 8.5gr between the beginning of the research and at the end of the 6 months therapy. We could arrive at the conclusion that the treatment with dutasteride in a 6 month period achieves 36.3% reduction of the need of use of the indwelling catheter, which would potentially reduce the possibility of a surgical resolution.

KEY WORDS: DUTASTERIDE, INDWELLING CATHETER, PSA, PROSTATIC WEIGHT.